Heart Failure

Taking the medication is linked to a 26% increase in new HF diagnosis, results of a study published in ESC Heart Failure show.

These benefits included increased survival, a lower risk of hospital readmission for heart failure, and an overall improvement in quality of life.

Vericiguat is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure.

mRNA encoding vascular endothelial growth factor into the myocardium of patients undergoing elective coronary artery bypass surgery was both safe and tolerable in patients with heart failure.

Bacteria, fungi, and other germs that cause endocarditis may enter the bloodstream through improper dental care, catheters, and IV drug use.

If approved, empagliflozin would be the first therapy proven to significantly improve outcomes for individuals with heart failure, according to Boehringer Ingelheim.

But expanding coverage in 2014 was associated with a notable increase in enrollment among individuals with heart failure, study results show.

Empagliflozin demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure, compared with placebo.

Compared to women who followed the Portfolio Diet less frequently, those with the closest alignment were 11% less likely to develop any type of cardiovascular disease, 14% less likely to develop coronary heart disease, and 17% less likely to develop heart failure.

In clinical trials, empagliflozin significantly reduced the relative risk of the primary composite endpoint of time to cardiovascular death or hospitalization for heart failure by 25%.

Its important for the patients with heart failure to know how much their ejection fraction is.

Ryan Jacobsen, PharmD, BCPS leads a discussion on defining heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) as well as the importance of staging and functional classification criteria.

Recently, many providers have become worried about the potential of certain medications to worsen transmission and outcomes in the setting of the global COVID-19 pandemic.

Results of the DAPA-HF trial demonstrate the efficacy and safety of dapagliflozin in patients with heart failure.

Staying on top of oral hygiene may be connected to a lower risk of atrial fibrillation and heart failure.

A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.

In honor of World Diabetes Day, AstraZeneca has launched the campaign Diabetes Can Break Your Heart, the national movement aimed to change the trajectory of heart failure in type 2 diabetes.

The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.

Top news of the day from across the health care landscape

“The central problem in heart failure is not that patients are short of breath or retain fluid. The problem is that they die.”

The findings of a retrospective study suggest that timing of heart failure (HF)-related pharmacotherapy following a HF-related encounter has potential implications on subsequent healthcare costs.

This may be the first drug shown to reduce mortality in the HFpEF population in the United States but will hopefully not be the last.

A number of landmark clinical studies on lipid lowering and cardiovascular health have been published, shaping how patients are treated.

Large clinical trial shows no increase in adverse events from treatment with aspirin for heart failure.

Even small weight gain may change the structure of the heart.

While overall hospitalizations for heart failure decreased, problems persist among minority populations.

This article highlights 5 published case reports that document unusual drug overdoses.

Investigational cancer drug blocks inflammation and fibrosis in heart cells.